A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

Name: A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Published: 2025
License: Public Domain

AbbVie · 2025

ClinicalTrials.gov · Datasets · License: Public Domain · 2025

Open Source ↗

cancer multiple-myeloma

multiple myeloma, abbv-453, surzetoclax, daratumumab, dexamethasone, pomalidomide, cancer, interventional, phase1, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

Related documents